MA41111B1 - Compositions anticancéreuses - Google Patents
Compositions anticancéreusesInfo
- Publication number
- MA41111B1 MA41111B1 MA41111A MA41111A MA41111B1 MA 41111 B1 MA41111 B1 MA 41111B1 MA 41111 A MA41111 A MA 41111A MA 41111 A MA41111 A MA 41111A MA 41111 B1 MA41111 B1 MA 41111B1
- Authority
- MA
- Morocco
- Prior art keywords
- hpmcas
- arn
- meth
- acrylate
- prostate cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 6
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 abstract 6
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 6
- 229920001577 copolymer Polymers 0.000 abstract 5
- 229920000193 polymethacrylate Polymers 0.000 abstract 5
- 239000007962 solid dispersion Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques d'arn-509, qui peuvent être administrées à un mammifère, en particulier un humain, souffrant d'une maladie ou affection liée à un récepteur d'androgène (ar), en particulier un cancer, plus particulièrement un cancer de la prostate comprenant, mais non limité à, un cancer de la prostate résistant à la castration, un cancer de la prostate résistant à la castration métastatique, un cancer de la prostate résistant à la castration métastatique naïf de chimiothérapie, un cancer de la prostate hormonosensible biochimiquement récidivant, ou un cancer de la prostate résistant à la castration, non métastatique, à haut risque. Dans un aspect, ces formulations comprennent une dispersion solide d'arn-509, un copolymère de poly(méth)acrylate et hpmcas. Dans un aspect, la dispersion solide d'arn-509, d'un copolymère de poly(méth)acrylate et de hpmcas est susceptible d'être obtenue, en particulier est obtenue, par extrusion à l'état fondu d'un mélange comprenant arn-509, un copolymère de poly(méth)acrylate et hpmcas et ensuite, facultativement, le broyage dudit mélange extrudé à l'état fondu. Dans un aspect, la dispersion solide d'arn-509, d'un copolymère de poly(méth)acrylate et de hpmcas peut être obtenue, en particulier est obtenue, par séchage par pulvérisation un mélange comprenant arn-509, un copolymère de poly(méth)acrylate et hpmcas dans un solvant adapté.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41111B1 true MA41111B1 (fr) | 2021-09-30 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41111A MA41111B1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10285948B2 (fr) |
| EP (2) | EP3226843B1 (fr) |
| JP (1) | JP6830892B2 (fr) |
| KR (1) | KR102387089B1 (fr) |
| CN (1) | CN106999432A (fr) |
| AR (1) | AR102925A1 (fr) |
| AU (1) | AU2015358497B2 (fr) |
| CA (1) | CA2969675C (fr) |
| CL (1) | CL2017001373A1 (fr) |
| CO (1) | CO2017005574A2 (fr) |
| CR (1) | CR20170218A (fr) |
| CY (1) | CY1124504T1 (fr) |
| DK (1) | DK3226843T3 (fr) |
| EA (1) | EA201791251A1 (fr) |
| ES (2) | ES2883187T3 (fr) |
| HR (1) | HRP20211140T1 (fr) |
| HU (1) | HUE054935T2 (fr) |
| IL (1) | IL252325A0 (fr) |
| LT (1) | LT3226843T (fr) |
| MA (1) | MA41111B1 (fr) |
| MD (1) | MD3226843T2 (fr) |
| MX (1) | MX381829B (fr) |
| MY (1) | MY192931A (fr) |
| NI (1) | NI201700068A (fr) |
| PH (1) | PH12017500979A1 (fr) |
| PL (1) | PL3226843T3 (fr) |
| PT (1) | PT3226843T (fr) |
| RS (1) | RS62421B1 (fr) |
| SG (1) | SG11201704386VA (fr) |
| SI (1) | SI3226843T1 (fr) |
| SM (1) | SMT202100454T1 (fr) |
| TW (1) | TWI709403B (fr) |
| UA (1) | UA123538C2 (fr) |
| WO (1) | WO2016090105A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013323861C1 (en) | 2012-09-26 | 2024-05-02 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| TWI709403B (zh) | 2014-12-05 | 2020-11-11 | 美商艾瑞岡醫藥公司 | 抗癌症組成物（二） |
| PL3226841T3 (pl) | 2014-12-05 | 2025-03-03 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| CN111479560A (zh) | 2017-10-16 | 2020-07-31 | 阿拉贡药品公司 | 用于治疗非转移性去势难治性前列腺癌的抗雄激素 |
| WO2020144650A1 (fr) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgènes pour le traitement du cancer de la prostate |
| AU2020215177A1 (en) | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| AU2020215176B2 (en) | 2019-01-30 | 2025-02-27 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020239478A1 (fr) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques |
| CA3160121A1 (fr) | 2019-11-04 | 2021-05-14 | Aragon Pharmaceuticals, Inc. | Inhibiteurs du recepteur des androgenes pour le traitement du cancer de la prostate non metastatique resistant a la castration chez des sujets presentant une deficience hepatique grave |
| WO2021245285A1 (fr) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (fr) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Méthodes de traitement du cancer de la prostate |
| WO2023152611A1 (fr) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide et relugolix pour le traitement du cancer de la prostate |
| WO2023209555A1 (fr) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate |
| AU2024236119A1 (en) | 2023-03-16 | 2025-09-25 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020097A1 (fr) | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | Steroïdes substitues-17 utiles pour le traitement du cancer |
| EP0901786B1 (fr) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Dispersions solides pharmaceutiques à biodisponibilité accrue |
| AU2001232348A1 (en) | 2000-02-21 | 2001-08-27 | Takeda Chemical Industries Ltd. | Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same |
| EP1368001B1 (fr) | 2001-02-27 | 2005-10-26 | AstraZeneca AB | Preparation pharmaceutique comprenant du bicalutamide |
| EE200300476A (et) | 2001-04-02 | 2003-12-15 | Astrazeneca Ab | 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon |
| ATE480226T1 (de) | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| CA2474958A1 (fr) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection |
| WO2003077827A1 (fr) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
| AU2003292509B2 (en) | 2003-12-15 | 2007-08-02 | Council Of Scientific And Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| SI2656841T1 (sl) | 2006-03-27 | 2016-11-30 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji |
| EA022924B1 (ru) * | 2009-04-03 | 2016-03-31 | Ф.Хоффманн-Ля Рош Аг | ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ |
| LT3124481T (lt) | 2010-02-16 | 2018-06-11 | Aragon Pharmaceuticals, Inc. | Androgeno receptorių moduliatoriai ir jų panaudojimas |
| CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| EP2721003B1 (fr) | 2011-06-15 | 2018-01-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Modulateurs de récepteurs nucléaires et leur utilisation pour le traitement et la prévention d'un cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (fr) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Inhibiteur de mtor anticancéreux et combinaison anti-androgène |
| PL3533792T3 (pl) * | 2012-06-07 | 2021-11-29 | Aragon Pharmaceuticals, Inc. | Postacie krystaliczne modulatora receptora androgenowego |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| BR112015002055A2 (pt) | 2012-08-24 | 2017-07-04 | Dow Global Technologies Llc | acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório |
| CN105358535B (zh) * | 2012-09-11 | 2019-01-04 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| AU2013323861C1 (en) * | 2012-09-26 | 2024-05-02 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| HK1211217A1 (en) | 2013-01-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition with improved bioavailability |
| KR102121404B1 (ko) | 2013-03-15 | 2020-06-11 | 썬 파마 글로벌 에프제트이 | 아비라테론 아세테이트 제제 |
| WO2014167428A2 (fr) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe |
| US9808472B2 (en) | 2013-08-12 | 2017-11-07 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| WO2015116696A1 (fr) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Thérapies de combinaison et procédés d'utilisation associés pour le traitement du cancer |
| EA037895B1 (ru) * | 2014-02-05 | 2021-06-02 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
| NZ719654A (en) | 2014-02-06 | 2020-06-26 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| TWI709403B (zh) | 2014-12-05 | 2020-11-11 | 美商艾瑞岡醫藥公司 | 抗癌症組成物（二） |
| KR102348325B1 (ko) | 2014-12-05 | 2022-01-06 | 아라곤 파마슈티컬스, 인코포레이티드 | 항암 조성물 |
| PL3226841T3 (pl) | 2014-12-05 | 2025-03-03 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| UA124154C2 (uk) * | 2016-06-03 | 2021-07-28 | Арагон Фармасьютікалз, Інк. | Протиракові композиції |
-
2015
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/fr not_active Ceased
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/fr active Active
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 ES ES21175525T patent/ES3019912T3/es active Active
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/fr active Active
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/fr active Active
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro not_active IP Right Cessation
- 2015-12-03 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41111B1 (fr) | Compositions anticancéreuses | |
| MA41107B1 (fr) | Compositions anti-cancéreuses | |
| MA41108A (fr) | Compositions anticancéreuses | |
| PH12018502334A1 (en) | Anticancer compositions | |
| EP3356522A4 (fr) | Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants | |
| EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
| MA44693A1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
| MA37809B1 (fr) | Administration de médicament biodégradable pour compositions hydrophobes | |
| MA33405B1 (fr) | Anticorps anti-axl | |
| EP2331092A4 (fr) | Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer | |
| EA202191914A1 (ru) | Бесследные линкеры и их белок-конъюгаты | |
| TH170798A (th) | องค์ประกอบต้านมะเร็ง | |
| MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |